| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
APx Acquisition Corp. I (NASDAQ:APXI) ("APx"), a publicly traded special purpose acquisition company, OmnigenicsAI Corp ("OmnigenicsAI"), a precision medicine company incubated by Bioceres Group PLC, and MultiplAI Health Ltd ("MultiplAI"), a UK-based AI-enabled preventive medicine company, have entered into a definitive Business Combination Agreement ("BCA") that, upon closing, would result in OmnigenicsAI becoming a publicly listed company. The transaction is expected to close mid-year, subject to the approval of APx's shareholders and other customary closing conditions and, upon closing, OmnigenicsAI's shares are expected to be listed on Nasdaq under the ticker symbol "OMNI".
The strategic combination creates a global AI-driven genomics company, focused on providing secure, precise, and reliable biological data. The integration of AI with precision medicine enables the interpretation of complex genomic data at an unprecedented scale, allowing for the delivery of highly personalized health insights, and clinical and therapeutic guidance.
OmnigenicsAI will offer a comprehensive suite of health evaluation services, in the following categories:
(1) Prevention: nutrition-based health risk-management that provides DNA and microbiome insights to understand how unique genes and habits impact long-term health, fostering preventive health strategies;
(2) Early Detection: RNA screening aimed at the early detection of complex diseases such as cardiovascular disease, by analyzing genomic relationships through blood tests; and
(3) Diagnostics and Treatment: specialized clinical genetic tests to enable personalized diagnostics and treatment, covering the fields of oncology, prenatal care, rare diseases and human microbiome, and complemented by telemedicine consultations with medical geneticists.
The combined company is expected to benefit from a highly accomplished global executive team, bolstered data science and R&D capabilities, as well as an expanded geographic footprint beyond Latin America into the United Kingdom and United States, particularly through key clinical and commercial partnerships.
Chairman of APx, Kyle Bransfield said: "This strategic merger not only reflects our innovative ethos at APx, but is also expected to position OmnigenicsAI at the vanguard of a global movement towards health equity and excellence."
"OmnigenicsAI is pioneering a new category of healthcare that integrates the groundbreaking potential of artificial intelligence with today´s access to vast amounts of genomic data, to provide personalized insights that empower individuals to make informed health decisions throughout their lives" said Mark Ramondt, CFO and COO of MultiplAI and CEO nominee of OmnigenicsAI.
Posted In: APXI
